The Johnson & Johnson vaccine is seen as a beacon of hope because one dose is enough and it is easier to store. But doubts about the promised delivery to the EU are apparently growing.
Another Covid-19 vaccine manufacturer may face delivery problems. The US pharmaceutical company Johnson & Johnson (J&J) has told the EU that it is struggling with problems that could complicate the planned delivery of 55 million vaccine doses in the second quarter, as the news agency Reuters learned from an EU representative.
Last week, J&J announced that the company was “under stress” to meet its delivery target by the end of June due to problems with supplies of vaccine ingredients and equipment. According to the insider, the group has said it will not rule out reaching the goal, but J&J is careful.
EU is waiting for 200 million cans from Johnson & Johnson
J&J did not want to comment on this and stated that the group expected to be able to start delivering the promised vaccine doses to the European Union in the second quarter. A spokesman for the EU Commission did not want to comment. The international community has secured a total of 200 million cans from the company this year.
The European Medicines Agency (Ema) is expected to give the go-ahead for the vaccine on March 11th. It is considered a beacon of hope because it does not have to be cooled as much as other vaccines and only one dose has to be inoculated.
So far, Covid-19 vaccines from Biontech / Pfizer, Moderna and Astrazeneca have been approved in the EU. There were also delivery delays here. The manufacturing process is complex, the facilities for it are limited and there are supply bottlenecks for components.